$385 Million is the total value of Essex Woodlands Management, Inc.'s 8 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was - .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
MDXG | New | MIMEDX GROUP, INC. | $177,623,000 | – | 19,480,519 | +100.0% | 46.09% | – |
EYPT | New | EYEPOINT PHARMACEUTICALS INC | $27,576,000 | – | 4,190,921 | +100.0% | 7.16% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-12
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
MEDICINOVA INC | 45 | Q2 2024 | 6.5% |
REVANCE THERAPEUTICS INC | 42 | Q2 2024 | 44.6% |
AXOGEN INC | 26 | Q4 2021 | 43.3% |
ENDOLOGIX INC | 24 | Q1 2019 | 22.5% |
ABIOMED INC | 20 | Q1 2018 | 52.1% |
CORIUM INTL INC | 20 | Q1 2019 | 23.5% |
TELA BIO, INC. | 19 | Q2 2024 | 31.5% |
VENUS CONCEPT, INC. | 17 | Q4 2023 | 21.3% |
EYEPOINT PHARMACEUTICALS INC | 15 | Q2 2024 | 27.6% |
ACURA PHARMACEUTICALS INC | 15 | Q1 2019 | 1.4% |
View Essex Woodlands Management, Inc.'s complete holdings history.
Latest filings
Type | Filed |
---|---|
N-PX | 2024-08-30 |
13F-HR | 2024-08-14 |
13F-HR | 2024-05-15 |
13F-HR | 2024-02-14 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-14 |
13F-HR | 2023-05-15 |
13F-HR | 2023-02-14 |
13F-HR | 2022-11-14 |
13F-HR | 2022-08-15 |
View Essex Woodlands Management, Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.